




RealRate

HEALTH SERVICES 2021

Viridian Therapeutics Inc DE
Rank 20 of 78



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Viridian Therapeutics Inc DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viridian Therapeutics Inc DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 382% points. The greatest weakness of Viridian Therapeutics Inc DE is the variable Net Income, reducing the Economic Capital Ratio by 127% points.

The company's Economic Capital Ratio, given in the ranking table, is 313%, being 183% points above the market average of 130%.

Input Variable	Value in 1000 USD
Assets, Current	129,611
Assets, Non-Current	1,335
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	13,265
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	10,674
Long Term Liabilities	544
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	-8.0
Other Expenses	98,673
Other Liabilities	0
Other Net Income	173
Other Revenues	1,050
Property Plant and Equipment	309
Research And Development Expense	0
Selling and Marketing Expense	0

Output Variable	Value in 1000 USD
Assets	131,255
Liabilities	11,218
Expenses	111,938
Revenues	1,050
Stockholders Equity	120,037
Net Income	-110,715
Comprehensive Net Income	-110,723
Economic Capital Ratio	313%